Drug
Tinostamustine clinical trials
Also written EDO-S101.
- studies test it
- 6
- open now
- 1
- in phase 3
- 1
- first study started
- 2016
Keep track of what changes. Save the tinostamustine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
6 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 4
- Phase 2
- 3
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 2
Mundipharma Research Limited (3) · Global Coalition for Adaptive Research (1) · Mundipharma-EDO GmbH (1) · Markus Joerger (1)
Often tested with
Tested in the same studies.
Regorafenib (1) · GDC-0084 (1) · Dianhydrogalactitol (1) · TSP-1 Activator VT1021 (1) · Troriluzole (1) · Pegargiminase (1) · AZD1390 (1)
Studies
Open first, then newest update. How each study uses tinostamustine is read from its arms, and is right about nine times in ten.
Testing it · 6
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaRecruitingPhase 2/3Global Coalition for Adaptive ResearchNCT03970447Written as Tinostamustine
- Study of Tinostamustine for Adjuvant Treatment of GlioblastomaCompletedEarly Phase 1Mundipharma Research LimitedNCT05432375Written as Tinostamustine
- Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.CompletedPhase 1/2Mundipharma Research LimitedNCT03345485Written as Tinostamustine 60mg/m2 over 30min
- Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic MalignanciesCompletedPhase 1Mundipharma Research LimitedNCT02576496Written as Tinostamustine
- Tinostamustine Conditioning and Autologous Stem CellTerminatedPhase 1/2Mundipharma-EDO GmbHNCT03687125Written as Tinostamustine
- Tinostamustine and Nivolumab in Advanced MelanomaStatus unknownPhase 1Markus JoergerNCT03903458Written as Tinostamustine
Given in every arm · 1 — tinostamustine is usual care beside what is tested
Codes
What other systems call tinostamustine · ClinicalTrials.gg INT000521
- MeSH (NLM) C000609929tinostamustineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 29DKI2H2NYTINOSTAMUSTINEConfirmed FDA, NLM
- NCI Thesaurus C126105TinostamustineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000609929 | tinostamustine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 29DKI2H2NY | TINOSTAMUSTINE | Confirmed FDA, NLM |
| NCI Thesaurus | C126105 | Tinostamustine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.